{
  "drugid": "RxNorm:2054023",
  "drugname": "tafenoquine",
  "guidelinename": "G6PD",
  "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/",
  "guidelinepharmgkbids": [
    "PA166119846"
  ],
  "citations": [
    {
      "pmid": "36049896",
      "title": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.",
      "authors": [
        "Gammal Roseann S",
        "Pirmohamed Munir",
        "Somogyi Andrew A",
        "Morris Sarah A",
        "Formea Christine M",
        "Elchynski Amanda L",
        "Oshikoya Kazeem A",
        "McLeod Howard L",
        "Haidar Cyrine E",
        "Whirl-Carrillo Michelle",
        "Klein Teri E",
        "Caudle Kelly E",
        "Relling Mary V"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2022
    }
  ],
  "recommendations": [
    {
      "implications": {
        "G6PD": "High risk of acute hemolytic anemia"
      },
      "drugrecommendation": "Avoid use",
      "classification": "Strong",
      "phenotypes": {
        "G6PD": "Deficient"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "G6PD": "Deficient"
      },
      "comments": null,
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "G6PD": "High risk of acute exacerbation of chronic hemolysis"
      },
      "drugrecommendation": "Avoid use",
      "classification": "Strong",
      "phenotypes": {
        "G6PD": "Deficient with CNSHA"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "G6PD": "Deficient with CNSHA"
      },
      "comments": "Although there are not published data in individuals with the G6PD Deficient with CNSHA phenotype, there is a strong rationale to avoid these drugs based on evidence in G6PD Deficient individuals.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "G6PD": "Unknown risk of acute hemolytic anemia"
      },
      "drugrecommendation": "To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",
      "classification": "Moderate",
      "phenotypes": {
        "G6PD": "Indeterminate"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "G6PD": "Indeterminate"
      },
      "comments": null,
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "G6PD": "Low risk of acute hemolytic anemia"
      },
      "drugrecommendation": "No reason to avoid based on G6PD status",
      "classification": "Strong",
      "phenotypes": {
        "G6PD": "Normal"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "G6PD": "Normal"
      },
      "comments": "Tafenoquine’s safety has been established for a G6PD enzyme activity ≥70% of normal. (Inclusion criteria for clinical trials involving tafenoquine included G6PD activity ≥70%.)",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "G6PD": "Variable risk of acute hemolytic anemia"
      },
      "drugrecommendation": "To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",
      "classification": "Moderate",
      "phenotypes": {
        "G6PD": "Variable"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "G6PD": "Variable"
      },
      "comments": "Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype; an enzyme activity test is needed to assign G6PD phenotype in such cases. Tafenoquine’s safety has been established for a G6PD enzyme activity ≥70% of normal. (Inclusion criteria for clinical trials involving tafenoquine included G6PD activity ≥70%.)",
      "population": "general",
      "genotypes": null
    }
  ],
  "genes": [
    "G6PD"
  ],
  "notesonusage": null,
  "cpicVersion": "v1.21.0",
  "source": "CPIC"
}